Leuconostoc mesenteroides capable of assisting weight management and application, product and method thereof

Abstract

The invention relates to leuconostoc mesenteroides capable of assisting weight management and application, a product and a method thereof, and relates to the technical field of probiotic compositions.The probiotic composition for improving obesity is prepared from, by weight, 10-60 parts of lactobacillus rhamnosus PB-LR76, 10-60 parts of lactobacillus helveticus HH-LPH17, 10-80 parts of lactobacillus casei PB-LC39 and 10-60 parts of lactobacillus fermentum HH-LF392. The feed additive comprises the following components in parts by weight: 10-60 parts of leuconostoc mesenteroides subsp. Mesenteroides MUM502 and 10-60 parts of lactobacillus reuteri PB-LR09. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for improving obesity is prepared, and a safe and effective new method is provided for weight management of obese people.

Description

Technical Field

[0001] This invention relates to the field of probiotic composition technology, and more particularly to a strain of Leuconostoc mesenteroides that can assist in weight management, as well as its applications, products and methods. Background Technology

[0002] Overweight and obesity not only significantly increase the risk of various complications but are also closely linked to mortality, becoming the leading risk factor for preventable diseases and disability. Obesity increases the risk of early death and raises the overall mortality rate. Its pathogenic mechanisms are complex and diverse. On the one hand, excessive accumulation of adipose tissue produces a mass effect; on the other hand, it directly triggers metabolic disorders. These two effects work together and are closely related to the development of various chronic diseases. Specifically, obesity is associated with an increased risk of diabetes, stroke, coronary artery disease, hypertension, respiratory diseases, obstructive sleep apnea, osteoarthritis, and gallstones. Furthermore, numerous studies have shown that obesity is also associated with the development of various cancers. Moreover, obesity has a significant negative impact on an individual's mental health and social functioning.

[0003] Currently, obesity treatment strategies mainly encompass drug therapy and surgical treatment. Drug therapy, such as mesalazine enteric-coated tablets and sulfasalazine, can be used in combination with glucocorticoids (such as prednisolone and budesonide) during disease activity. However, drug therapy has certain limitations, may be accompanied by significant side effects, and patients are prone to weight rebound after discontinuation of medication. Surgical treatment is mainly suitable for critically ill patients, such as those experiencing massive bleeding, intestinal perforation, or those who have not responded to aggressive treatment and are accompanied by severe toxemia. However, surgical treatment is expensive, has a relatively high recurrence rate, and carries certain surgical risks.

[0004] In view of the above, developing a safe and effective new method to improve obesity in obese people is of great practical significance and urgency. Summary of the Invention

[0005] To address the aforementioned issues, this invention provides a strain of Leuconostoc mesenteroides that can assist in weight management, along with its applications, products, and methods.

[0006] In a first aspect, the present invention provides a probiotic composition for improving obesity, wherein, by weight, the probiotic composition for improving obesity comprises the following components:

[0007] Lactobacillus rhamnosus PB-LR76 10-60 samples, Lactobacillus helveticus HH-LPH17 10-60 samples, Lactobacillus casei PB-LC39 10-80 samples, Lactobacillus fermentum HH-LF392 10-60 samples, Leuconostoc mesenteroides subsp. mesenteroides MUM502 10-60 samples, Lactobacillus reuteri PB-LR09 10-60 samples.

[0008] Furthermore, 20 samples of Lactobacillus rhamnosus PB-LR76, 20 samples of Lactobacillus helveticus HH-LPH17, 30 samples of Lactobacillus casei PB-LC39, 10 samples of Lactobacillus fermentum HH-LF392, 10 samples of Leuconostoc mesenteroides subsp. mesenteroides MUM502, and 10 samples of Lactobacillus reuteri PB-LR09 were collected.

[0009] Secondly, based on the same inventive concept, the present invention provides the use of the probiotic composition for improving obesity as described in any one of the first aspects in the preparation of products for improving obesity.

[0010] The technical solutions provided in the embodiments of the present invention have at least the following advantages compared with the prior art:

[0011] This invention provides a strain of Leuconostoc mesenteroides that can assist in weight management, as well as its applications, products, and methods. This invention screens probiotic strains with specific effects and optimizes their combination ratio to prepare a probiotic composition for improving obesity, providing a safe and effective new method for weight management in obese individuals. Detailed Implementation

[0012] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0013] Unless otherwise specified, all raw materials, reagents, instruments and equipment used in this invention can be purchased from the market or prepared by existing methods.

[0014] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed according to national standards. If no corresponding national standard exists, then generally accepted international standards, conventional conditions, or conditions recommended by the manufacturer are followed.

[0015] The strain information involved in this invention is as follows:

[0016] The Leuconostoc mesenteroides subsp. mesenteroides MUM502 was deposited on May 9, 2024, at the China Center for Type Culture Collection (CCTCC), located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, China, with accession number CCTCC NO: M2024885.

[0017] The specific preservation information of Lactobacillus rhamnosus PB-LR76 is as follows: it was deposited on December 12, 2018 at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, with accession number CCTCC NO:M 2018887.

[0018] The specific preservation information of the Lactobacillus helveticus HH-LPH17 is as follows: it was deposited on June 15, 2021 at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, with accession number CCTCC NO:M 2021725.

[0019] The specific preservation information of Lactobacillus casei PB-LC39 is as follows: it was deposited at the China Center for Type Culture Collection on December 12, 2018, at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, with accession number CCTCC NO:M 2018886.

[0020] The specific preservation information for Lactobacillus fermentum HH-LF392 is that it was deposited on June 15, 2021, at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, with accession number CCTCCNO:M 2021724.

[0021] The specific preservation information of the Lactobacillus reuteri PB-LR09 is as follows: it was deposited on December 12, 2018 at the China Center for Type Culture Collection, located at No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, with accession number CCTCC NO:M 2018888.

[0022] Example 1

[0023] This example provides a probiotic composition for improving obesity, which, by weight, comprises the following components:

[0024] 20 samples of Lactobacillus rhamnosus PB-LR76, 20 samples of Lactobacillus helveticus HH-LPH17, 30 samples of Lactobacillus casei PB-LC39, 10 samples of Lactobacillus fermentum HH-LF392, 10 samples of Leuconostoc mesenteroides subsp. mesenteroides MUM502, and 10 samples of Lactobacillus reuteri PB-LR09.

[0025] The preparation method of the above-mentioned probiotic composition for improving obesity includes: mixing the various probiotics to form a compound bacterial powder.

[0026] Example 2

[0027] This example provides a probiotic composition for improving obesity, which, by weight, comprises the following components:

[0028] 10 samples of Lactobacillus rhamnosus PB-LR76, 10 samples of Lactobacillus helveticus HH-LPH17, 10 samples of Lactobacillus casei PB-LC39, 10 samples of Lactobacillus fermentum HH-LF392, 10 samples of Leuconostoc mesenteroides subsp. mesenteroides MUM502, and 10 samples of Lactobacillus reuteri PB-LR09.

[0029] The preparation method of the above-mentioned probiotic composition for improving obesity includes: mixing the various probiotics to form a compound bacterial powder.

[0030] Example 3

[0031] This example provides a probiotic composition for improving obesity, which, by weight, comprises the following components:

[0032] Lactobacillus rhamnosus PB-LR76 60 samples, Lactobacillus helveticus HH-LPH17 60 samples, Lactobacillus casei PB-LC39 80 samples, Lactobacillus fermentum HH-LF392 60 samples, Leuconostoc mesenteroides subsp. mesenteroides MUM502 60 samples, Lactobacillus reuteri PB-LR09 60 samples.

[0033] The preparation method of the above-mentioned probiotic composition for improving obesity includes: mixing the various probiotics to form a compound bacterial powder.

[0034] Test case

[0035] This example aims to examine the therapeutic effect of the probiotic composition obtained in Example 1 above for improving obesity on rheumatoid arthritis.

[0036] Test method: Healthy four-week-old male C57BL / 6J mice were housed in an SPF-grade environment at 20-25℃, with alternating 12 hours of daylight / 12 hours of darkness in the animal room. After one week of acclimatization with free access to water and a basal maintenance diet, the mice were weighed and randomly divided into 5 groups of 10 mice each. The grouping was as follows: (1) Control group: basal diet + PBS; (2) Model group: high-fat diet (HFD) + PBS; (3) Low-dose group: high-fat diet + 1×10 8 CFU powder; (4) Medium dose group: high-fat diet + 5×10 8 CFU powder; (5) High-dose group: high-fat diet + 1×10 9 CFU powder was mixed in. Mice were gavaged with 0.3 mL of the powder at 9:30 a.m. every day for 8 consecutive weeks, and relevant indicators were measured.

[0037] 1. Weight Changes: After 8 weeks of gavage drug intervention, different doses of probiotic powder all showed varying degrees of reduction in weight gain in hyperfat obese mice, and all were lower than those in the model group. Among them, the high-dose experimental group had the most significant effect on reducing weight gain in hyperfat obese mice, with a weight gain rate of 23.8% (25.2% in the basal group and 46.8% in the high-fat diet group), as shown in Table 1.

[0038] 2. Organ Index: To further explore the effect of probiotic mixed powder on fat deposition in obese model mice, liver and kidney tissues were separated and weighed. Obesity directly increases the burden on the liver and kidneys, leading to organ damage. As major metabolic organs, the weight of the liver and kidneys reflects the fat storage status in mice to some extent. As shown in the table above, different doses of probiotic mixed powder showed a downward trend in the weight of the liver and kidneys in the experimental mice, with significant differences compared to the model group, thus alleviating the organ burden caused by excessive obesity to some extent, as shown in Table 2.

[0039] 3. Epididymal Fat: Epididymal fat is white adipose tissue, and its organ index partially reflects the fat storage status in mice. Compared with the model group, the weight of epididymal adipose tissue in all three experimental groups showed a significant decreasing trend, indicating a reduction in fat storage in mice, as shown in Table 3.

[0040] 4. Lipid Profile: A high-fat diet can lead to obesity and abnormal lipid metabolism. This study investigated the therapeutic effects of different doses of the mixed-powder product on lipid abnormalities induced by HFD (high-fat diet-induced hypertension). The four lipid parameters (TC, TG, LDL-C, and HDL-C) were measured. Compared with the control group, the model group showed significantly increased TC, TG, and LDL-C, and significantly decreased HDL-C. The probiotic mixed-powder significantly reduced serum total cholesterol, triglycerides, and low-density lipoprotein (LDL), while increasing serum high-density lipoprotein (HDL) cholesterol. This suggests that the product can regulate lipid metabolism to some extent, as shown in Table 4.

[0041] Table 1

[0042]

[0043] Table 2

[0044]

[0045]

[0046] Table 3

[0047]

[0048]

[0049] Table 4

[0050]

[0051] Various embodiments of the present invention may exist in the form of a range; it should be understood that the description in the form of a range is merely for convenience and brevity and should not be construed as a hard limitation on the scope of the invention; therefore, it should be considered that the range description has specifically disclosed all possible subranges and single numerical values ​​within that range. For example, it should be considered that the range description from 1 to 6 has specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and single numbers within the range, such as 1, 2, 3, 4, 5, and 6, regardless of the range. Furthermore, whenever a numerical range is referred to herein, it means including any referenced number (fraction or integer) within the range referred to.

[0052] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the present invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features claimed herein.

Claims

1. A probiotic composition for improving obesity, characterized in that, The probiotic composition for improving obesity comprises the following components in parts by weight: Lactobacillus rhamnosus PB-LR76 10-60 samples, Lactobacillus helveticus HH-LPH17 10-60 samples, Lactobacillus casei PB-LC39 10-80 samples, Lactobacillus fermentum HH-LF392 10-60 samples, Leuconostoc mesenteroides subsp. mesenteroides MUM502 10-60 samples, Lactobacillus reuteri PB-LR09 10-60 samples.

2. The probiotic composition for improving obesity according to claim 1, characterized in that, 20 samples of Lactobacillus rhamnosus PB-LR76, 20 samples of Lactobacillus helveticus HH-LPH17, 30 samples of Lactobacillus casei PB-LC39, 10 samples of Lactobacillus fermentum HH-LF392, 10 samples of Leuconostoc mesenteroides subsp. mesenteroides MUM502, and 10 samples of Lactobacillus reuteri PB-LR09.

3. The use of the probiotic composition for improving obesity according to any one of claims 1 to 2 in the preparation of a product for improving obesity.

Images